Probucol affords neuroprotection in a 6-OHDA mouse model of Parkinson's disease

Neurochemical Research

Volumn 38, Issue 3, 2013, Pages 660-668

  Ribeiro, Renata Pietsch ^a,b   Moreira, Eduardo Luiz Gasnhar ^a   Santos, Danúbia Bonfanti ^a   Colle, Dirleise ^a   Dos Santos, Alessandra Antunes ^a   Peres, Kaite Cristiane ^a   Figueiredo, Claudia Pinto ^c   Farina, Marcelo ^a  

^a FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

^b Science and Technology of Santa Catarina   (Brazil)

^c FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

6 Hydroxydopamine; Oxidative stress; Parkinson's disease; Probucol; Therapeutic strategies

Indexed keywords

CATALASE; OXIDOPAMINE; PROBUCOL; SUPEROXIDE DISMUTASE; SYNAPTOPHYSIN; TYROSINE 3 MONOOXYGENASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL STRESS; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; DRUG EFFECT; ENZYME ACTIVITY; ENZYME REGULATION; IN VIVO STUDY; LIPID PEROXIDATION; LOCOMOTION; MALE; METABOLIC PARAMETERS; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; MOUSE; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; TREATMENT DURATION; UPREGULATION;

ANIMALS; CATALASE; CORPUS STRIATUM; DOPAMINERGIC NEURONS; LIPID PEROXIDATION; MALE; MICE; MOTOR ACTIVITY; NEUROPROTECTIVE AGENTS; OXIDATIVE STRESS; OXIDOPAMINE; PARKINSON DISEASE; PROBUCOL; TYROSINE 3-MONOOXYGENASE;

MUS;

EID: 84876419766     PISSN: 03643190     EISSN: 15736903     Source Type: Journal    
DOI: 10.1007/s11064-012-0965-0     Document Type: Article

References (67)

1. Lang AE, Lozano AM (1998) Parkinson's disease. First of two parts. N Engl J Med 339(15):1044-1053. doi: 10.1056/NEJM199810083391506
2. Meissner WG (2012) When does Parkinson's disease begin? From prodromal disease to motor signs. Rev Neurol (Paris). doi: 10.1016/j.neurol.2012.07.004
3. Spica V, Pekmezovic T, Svetel M, Kostic VS (2012) Prevalence of non-motor symptoms in young-onset versus late-onset Parkinson's disease. J Neurol. doi: 10.1007/s00415-012-6600-9
4. Hirsch E, Graybiel AM, Agid YA (1988) Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease. Nature 334(6180):345-348. doi: 10.1038/334345a0
5. Schapira AH (2008) Progress in Parkinson's disease. Eur J Neurol 15(1):1. doi: 10.1111/j.1468-1331.2007.02036.x
6. Obeso JA, Rodriguez-Oroz MC, Goetz CG, Marin C, Kordower JH, Rodriguez M, Hirsch EC, Farrer M, Schapira AH, Halliday G (2010) Missing pieces in the Parkinson's disease puzzle. Nat Med 16(6):653-661. doi: 10.1038/nm.2165
7. Steece-Collier K, Maries E, Kordower JH (2002) Etiology of Parkinson's disease: genetics and environment revisited. Proc Natl Acad Sci USA 99(22):13972-13974. doi: 10.1073/pnas.242594999
8. Jenner P (2003) Oxidative stress in Parkinson's disease. Ann Neurol 53(Suppl 3):S26-S36. doi: 10.1002/ana.10483 (discussion S36-S28)
9. Zhou C, Huang Y, Przedborski S (2008) Oxidative stress in Parkinson's disease: a mechanism of pathogenic and therapeutic significance. Ann NY Acad Sci 1147:93-104. doi: 10.1196/annals.1427.023
10. Lotharius J, Brundin P (2002) Pathogenesis of Parkinson's disease: dopamine, vesicles and alpha-synuclein. Nat Rev Neurosci 3(12):932-942. doi: 10.1038/nrn983
11. Graham DG, Tiffany SM, Bell WR Jr, Gutknecht WF (1978) Autoxidation versus covalent binding of quinones as the mechanism of toxicity of dopamine, 6-hydroxydopamine, and related compounds toward C1300 neuroblastoma cells in vitro. Mol Pharmacol 14(4):644-653
12. Fukae J, Mizuno Y, Hattori N (2007) Mitochondrial dysfunction in Parkinson's disease. Mitochondrion 7(1-2):58-62. doi: 10.1016/j.mito.2006.12.002
13. Henchcliffe C, Beal MF (2008) Mitochondrial biology and oxidative stress in Parkinson disease pathogenesis. Nat Clin Pract Neurol 4(11):600-609. doi: 10.1038/ncpneuro0924
14. Langston JW (1996) The etiology of Parkinson's disease with emphasis on the MPTP story. Neurology 47(6 Suppl 3):S153-S160
15. Chinta SJ, Andersen JK (2008) Redox imbalance in Parkinson's disease. Biochim Biophys Acta 1780(11):1362-1367. doi: 10.1016/j.bbagen.2008.02.005
16. Martin HL, Teismann P (2009) Glutathione-a review on its role and significance in Parkinson's disease. FASEB J 23(10):3263-3272. doi: 10.1096/fj.08-125443
17. Bove J, Perier C (2011) Neurotoxin-based models of Parkinson's disease. Neuroscience 211:51-76. doi: 10.1016/j.neuroscience.2011.10.057
18. Glinka Y, Gassen M, Youdim MB (1997) Mechanism of 6-hydroxydopamine neurotoxicity. J Neural Transm Suppl 50:55-66
19. Kumar R, Agarwal AK, Seth PK (1995) Free radical-generated neurotoxicity of 6-hydroxydopamine. J Neurochem 64(4):1703-1707
20. Saner A, Thoenen H (1971) Model experiments on the molecular mechanism of action of 6-hydroxydopamine. Mol Pharmacol 7(2):147-154
21. Group TPS (1993) Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 328(3):176-183. doi: 10.1056/NEJM199301213280305
22. Shults CW, Oakes D, Kieburtz K, Beal MF, Haas R, Plumb S, Juncos JL, Nutt J, Shoulson I, Carter J, Kompoliti K, Perlmutter JS, Reich S, Stern M, Watts RL, Kurlan R, Molho E, Harrison M, Lew M (2002) Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol 59(10):1541-1550
23. Yamashita S, Hbujo H, Arai H, Harada-Shiba M, Matsui S, Fukushima M, Saito Y, Kita T, Matsuzawa Y (2008) Long-term probucol treatment prevents secondary cardiovascular events: a cohort study of patients with heterozygous familial hypercholesterolemia in Japan. J Atheroscler Thromb 15(6):292-303
24. Champagne D, Pearson D, Dea D, Rochford J, Poirier J (2003) The cholesterol-lowering drug probucol increases apolipoprotein E production in the hippocampus of aged rats: implications for Alzheimer's disease. Neuroscience 121(1):99-110
25. Park SY, Lee JH, Kim CD, Rhim BY, Hong KW, Lee WS (2007) Beneficial synergistic effects of concurrent treatment with cilostazol and probucol against focal cerebral ischemic injury in rats. Brain Res 1157:112-120. doi: 10.1016/j.brainres.2007.04.051
26. Santos DB, Peres KC, Ribeiro RP, Colle D, dos Santos AA, Moreira EL, Souza DO, Figueiredo CP, Farina M (2012) Probucol, a lipid-lowering drug, prevents cognitive and hippocampal synaptic impairments induced by amyloid beta peptide in mice. Exp Neurol 233(2):767-775. doi: 10.1016/j.expneurol.2011.11.036
27. Colle D, Hartwig JM, Soares FA, Farina M (2012) Probucol modulates oxidative stress and excitotoxicity in Huntington's disease models in vitro. Brain Res Bull 87:397-405. doi: 10.1016/j.brainresbull.2012.01.003
28. Farina M, Campos F, Vendrell I, Berenguer J, Barzi M, Pons S, Sunol C (2009) Probucol increases glutathione peroxidase-1 activity and displays long-lasting protection against methylmercury toxicity in cerebellar granule cells. Toxicol Sci 112(2):416-426. doi: 10.1093/toxsci/kfp219
29. Tanaka K, Ogawa N, Asanuma M (2006) Molecular basis of 6-hydroxydopamine-induced caspase activations due to increases in oxidative stress in the mouse striatum. Neurosci Lett 410(2):85-89. doi: 10.1016/j.neulet.2006.08.021
30. Laursen SE, Belknap JK (1986) Intracerebroventricular injections in mice. Some methodological refinements. J Pharmacol Methods 16(4):355-357
31. Prediger RD, Medeiros R, Pandolfo P, Duarte FS, Passos GF, Pesquero JB, Campos MM, Calixto JB, Takahashi RN (2008) Genetic deletion or antagonism of kinin B(1) and B(2) receptors improves cognitive deficits in a mouse model of Alzheimer's disease. Neuroscience 151(3):631-643. doi: 10.1016/j.neuroscience. 2007.11.009
32. Moreira EL, Rial D, Duarte FS, de Carvalho CR, Horst H, Pizzolatti MG, Prediger RD, Ribeiro-do-Valle RM (2010) Central nervous system activity of the proanthocyanidin-rich fraction obtained from Croton celtidifolius in rats. J Pharm Pharmacol 62(8):1061-1068. doi: 10.1111/j.2042-7158.2010.01124.x
33. Carlberg I, Mannervik B (1985) Glutathione reductase. Methods Enzymol 113:484-490
34. Wendel A (1981) Glutathione peroxidase. Methods Enzymol 77:325-333
35. Aebi H (1984) Catalase in vitro. Methods Enzymol 105:121-126
36. Misra HP, Fridovich I (1972) The role of superoxide anion in the autoxidation of epinephrine and a simple assay for superoxide dismutase. J Biol Chem 247(10):3170-3175
37. Ohkawa H, Ohishi N, Yagi K (1979) Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 95(2):351-358
38. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254
39. Kostrzewa RM, Reader TA, Descarries L (1998) Serotonin neural adaptations to ontogenetic loss of dopamine neurons in rat brain. J Neurochem 70(3):889-898
40. Reader TA, Dewar KM (1999) Effects of denervation and hyperinnervation on dopamine and serotonin systems in the rat neostriatum: implications for human Parkinson's disease. Neurochem Int 34(1):1-21
41. Janero DR (1990) Malondialdehyde and thiobarbituric acid-reactivity as diagnostic indices of lipid peroxidation and peroxidative tissue injury. Free Radic Biol Med 9(6):515-540
42. Mates JM, Perez-Gomez C, Nunez de Castro I (1999) Antioxidant enzymes and human diseases. Clin Biochem 32(8):595-603
43. Dringen R, Hirrlinger J (2003) Glutathione pathways in the brain. Biol Chem 384(4):505-516. doi: 10.1515/BC.2003.059
44. Kumer SC, Vrana KE (1996) Intricate regulation of tyrosine hydroxylase activity and gene expression. J Neurochem 67(2):443-462
45. Dexter DT, Carter CJ, Wells FR, Javoy-Agid F, Agid Y, Lees A, Jenner P, Marsden CD (1989) Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J Neurochem 52(2):381-389
46. Alam ZI, Jenner A, Daniel SE, Lees AJ, Cairns N, Marsden CD, Jenner P, Halliwell B (1997) Oxidative DNA damage in the parkinsonian brain: an apparent selective increase in 8-hydroxyguanine levels in substantia nigra. J Neurochem 69(3):1196-1203
47. Alam ZI, Daniel SE, Lees AJ, Marsden DC, Jenner P, Halliwell B (1997) A generalised increase in protein carbonyls in the brain in Parkinson's but not incidental Lewy body disease. J Neurochem 69(3):1326-1329
48. Floor E, Wetzel MG (1998) Increased protein oxidation in human substantia nigra pars compacta in comparison with basal ganglia and prefrontal cortex measured with an improved dinitrophenylhydrazine assay. J Neurochem 70(1):268-275
49. Di Matteo V, Esposito E (2003) Biochemical and therapeutic effects of antioxidants in the treatment of Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis. Curr Drug Targets CNS Neurol Disord 2(2):95-107
50. Beal MF (2001) Experimental models of Parkinson's disease. Nat Rev Neurosci 2(5):325-334. doi: 10.1038/35072550
51. Cohen G (1984) Oxy-radical toxicity in catecholamine neurons. Neurotoxicology 5(1):77-82
52. Soto-Otero R, Mendez-Alvarez E, Hermida-Ameijeiras A, Munoz-Patino AM, Labandeira-Garcia JL (2000) Autoxidation and neurotoxicity of 6-hydroxydopamine in the presence of some antioxidants: potential implication in relation to the pathogenesis of Parkinson's disease. J Neurochem 74(4):1605-1612
53. Ungerstedt U (1971) Postsynaptic supersensitivity after 6-hydroxy-dopamine induced degeneration of the nigro-striatal dopamine system. Acta Physiol Scand Suppl 367:69-93
54. Dringen R (2005) Oxidative and antioxidative potential of brain microglial cells. Antioxid Redox Signal 7(9-10):1223-1233. doi: 10.1089/ars.2005.7.1223
55. Dringen R, Pawlowski PG, Hirrlinger J (2005) Peroxide detoxification by brain cells. J Neurosci Res 79(1-2):157-165. doi: 10.1002/jnr.20280
56. Ghosh N, Ghosh R, Mandal SC (2011) Antioxidant protection: a promising therapeutic intervention in neurodegenerative disease. Free Radic Res 45(8):888-905. doi: 10.3109/10715762.2011.574290
57. Baud O, Greene AE, Li J, Wang H, Volpe JJ, Rosenberg PA (2004) Glutathione peroxidase-catalase cooperativity is required for resistance to hydrogen peroxide by mature rat oligodendrocytes. J Neurosci 24(7):1531-1540. doi: 10.1523/JNEUROSCI.3989-03.2004
58. Mozaffar S, Ueda M, Kitatsuji K, Shimizu S, Osumi M, Tanaka A (1986) Properties of catalase purified from a methanol-grown yeast, Kloeckera sp. 2201. Eur J Biochem 155(3):527-531
59. Farina M, Frizzo ME, Soares FA, Schwalm FD, Dietrich MO, Zeni G, Rocha JB, Souza DO (2003) Ebselen protects against methylmercury-induced inhibition of glutamate uptake by cortical slices from adult mice. Toxicol Lett 144(3):351-357
60. McCord JM, Fridovich I (1988) Superoxide dismutase: the first twenty years (1968-1988). Free Radic Biol Med 5(5-6):363-369
61. Oh SH, Lim SC (2006) A rapid and transient ROS generation by cadmium triggers apoptosis via caspase-dependent pathway in HepG2 cells and this is inhibited through N-acetylcysteine-mediated catalase upregulation. Toxicol Appl Pharmacol 212(3):212-223. doi: 10.1016/j.taap.2005.07.018
62. Terland O, Flatmark T, Tangeras A, Gronberg M (1997) Dopamine oxidation generates an oxidative stress mediated by dopamine semiquinone and unrelated to reactive oxygen species. J Mol Cell Cardiol 29(6):1731-1738. doi: 10.1006/jmcc.1997.0412
63. Bridges AB, Scott NA, Belch JJ (1991) Probucol, a superoxide free radical scavenger in vitro. Atherosclerosis 89(2-3):263-265
64. Kalyanaraman B, Darley-Usmar VM, Wood J, Joseph J, Parthasarathy S (1992) Synergistic interaction between the probucol phenoxyl radical and ascorbic acid in inhibiting the oxidation of low density lipoprotein. J Biol Chem 267(10):6789-6795
65. Ebadi M, Sharma SK (2003) Peroxynitrite and mitochondrial dysfunction in the pathogenesis of Parkinson's disease. Antioxid Redox Signal 5(3):319-335. doi: 10.1089/152308603322110896
66. Jenner P, Olanow CW (1996) Oxidative stress and the pathogenesis of Parkinson's disease. Neurology 47(6 Suppl 3):S161-S170
67. Yamashita S, Matsuzawa Y (2009) Where are we with probucol: a new life for an old drug? Atherosclerosis 207(1):16-23. doi: 10.1016/j.atherosclerosis. 2009.04.002